141 related articles for article (PubMed ID: 8684518)
1. Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy.
Rapoport J; Mostoslavski M; Ben-David A; Knecht A; Blau A; Arad J; Zlotnik M; Chaimovitz C
Nephron; 1996; 72(2):150-4. PubMed ID: 8684518
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
4. [Effect of pulse therapy using 1 alpha(OH)D on secondary hyperparathyroidism in patients on maintenance hemodialysis].
Yoshida K; Hirayama A; Tanaka N; Yasukawa M; Saka M; Kaneko Y; Maruyama Y; Motomiya Y; Ozono S; Hirao Y
Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1117-23. PubMed ID: 2287104
[TBL] [Abstract][Full Text] [Related]
5. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
[TBL] [Abstract][Full Text] [Related]
6. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis.
Brandi L; Daugaard H; Tvedegaard E; Nielsen PK; Egsmose C; Storm T; Olgaard K
Am J Nephrol; 1992; 12(5):311-8. PubMed ID: 1488999
[TBL] [Abstract][Full Text] [Related]
7. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism.
Tan AU; Levine BS; Mazess RB; Kyllo DM; Bishop CW; Knutson JC; Kleinman KS; Coburn JW
Kidney Int; 1997 Jan; 51(1):317-23. PubMed ID: 8995749
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
9. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
10. Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements.
Teruel JL; Tenorio MT; Rodríguez JR; Marc n R; Orofino L; Rivera M; Ortuño J
Am J Nephrol; 1999; 19(3):428-32. PubMed ID: 10393383
[TBL] [Abstract][Full Text] [Related]
11. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
12. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
13. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
[TBL] [Abstract][Full Text] [Related]
14. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
Shigematsu T; Kawaguchi Y; Unemura S; Yamamoto H; Momose M; Yokoyama K; Wakabayashi Y; Ikeda M; Hasegawa T; Sakai O
Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673
[TBL] [Abstract][Full Text] [Related]
15. Intermittent intravenous followed by intermittent oral 1 alpha(OH)D3 treatment of secondary hyperparathyroidism in uraemia.
Brandi L; Daugaard H; Egsmose C; Tvedegaard E; Kjaerulff Nielsen P; Olgaard K
J Intern Med; 1996 Apr; 239(4):353-60. PubMed ID: 8774390
[TBL] [Abstract][Full Text] [Related]
16. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
Koskimies O; Ala-Houhala M
Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
[TBL] [Abstract][Full Text] [Related]
17. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
Alghareeb A; Sabry A; Bawadekji H; Alsaran K
Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
[TBL] [Abstract][Full Text] [Related]
18. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
[TBL] [Abstract][Full Text] [Related]
19. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]